New drug cocktail shows promise for Tough-to-Treat lung cancer
NCT ID NCT05601973
First seen Jan 26, 2026 · Last updated May 10, 2026 · Updated 19 times
Summary
This study tests a combination of three drugs (amivantamab, lazertinib, and bevacizumab) in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease worsened after previous treatment. The goal is to see if adding two drugs to a standard targeted therapy can shrink tumors. This is not a cure, as patients require ongoing treatment to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AO SM Misericorida Perugia
Perugia, Italy
-
Catalan Institute of Oncology
L'Hospitalet de Llobregat, Spain
-
Centre Hospitalier d'Avignon
Avignon, France
-
Centre Léon Bérard
Lyon, France
-
Chu Angers
Angers, France
-
Hospital Universitario Alicante Dr Balmis ISABIAL
Alicante, Spain
-
Hospital Universitario Basurto
Bilbao, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
-
Hospital Universitario de A Coruña
A Coruña, Spain
-
Hospital clínico universitario de Valladolid
Valladolid, Spain
-
Hôpitaux universitaires de Genève (HUG)
Geneva, Switzerland
-
ICO Badalona
Badalona, Spain
-
Istituto Oncologico della Svizzera Italiana
Bellinzona, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, Switzerland
-
Netherlands Cancer Institute (NKI)
Amsterdam, Netherlands
-
The Royal Marsden NHS Foundation Trust
London, United Kingdom
-
Universitätsklinik für Medizinische Onkologie, Inselspital
Bern, Switzerland
-
Vall d´Hebron University Hospital VHIO
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.